Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Patent Expirybreast cancer vaccinePositive

AI Analysis

Summary

Anixa Biosciences received Australian patent protection for its breast cancer vaccine composition, securing exclusive rights through 2040 and expanding its global intellectual property portfolio.

Outcome Details

Australian composition of matter patent granted for breast cancer vaccine

Importance:4/10

Sentiment:

0.60

intellectual propertypatentbreast cancervaccineAustraliaIP protection

Related Companies

$ANIX

Read the original article

Published by PR Newswire Biotech on September 21, 2026 12:45 PM

Read Original